• 1. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 2. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 3. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 4. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 5. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazole carboxylic acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles Pyrazole carboxylic acids and derivatives

1-(3,5-Dimethyl-1H-pyrazol-1-yl)methyl-1H-pyrazole-3-carboxylic Acid: A Comprehensive Overview

1-(3,5-Dimethyl-1H-pyrazol-1-yl)methyl-1H-pyrazole-3-carboxylic acid (CAS No. 1004192-86-2) is a unique compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, often referred to as a pyrazole derivative, is characterized by its distinctive molecular structure and potential biological activities. This article aims to provide a comprehensive overview of 1-(3,5-dimethyl-1H-pyrazol-1-yl)methyl-1H-pyrazole-3-carboxylic acid, including its chemical properties, synthesis methods, biological activities, and potential applications in drug development.

Chemical Properties and Structure

1-(3,5-Dimethyl-1H-pyrazol-1-yl)methyl-1H-pyrazole-3-carboxylic acid is a heterocyclic compound with a molecular formula of C₁₂H₁₄N₄O₂. The compound features a pyrazole ring with a carboxylic acid group and a substituted methyl group attached to the pyrazole ring. The presence of the dimethyl-substituted pyrazole moiety contributes to its unique chemical properties and potential biological activities. The compound's molecular weight is approximately 246.27 g/mol, and it is typically found as a white crystalline solid at room temperature.

Synthesis Methods

The synthesis of 1-(3,5-dimethyl-1H-pyrazol-1-yl)methyl-1H-pyrazole-3-carboxylic acid has been explored through various methodologies. One common approach involves the reaction of 3,5-dimethylpyrazole with an appropriate carboxylic acid derivative under suitable conditions. For example, the reaction of 3,5-dimethylpyrazole with methyl 3-bromomethylpyrazole carboxylate followed by hydrolysis can yield the desired product. Another method involves the coupling of 3,5-dimethylpyrazole with 3-(bromomethyl)pyrazole using palladium-catalyzed cross-coupling reactions. These synthetic routes have been optimized to achieve high yields and purity levels, making them suitable for large-scale production in pharmaceutical settings.

Biological Activities and Mechanisms of Action

1-(3,5-Dimethyl-1H-pyrazol-1-yl)methyl-1H-pyrazole-3-carboxylic acid has been investigated for its potential biological activities, particularly in the context of anti-inflammatory and anti-cancer properties. Recent studies have shown that this compound exhibits significant anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines such as TNF-alpha and IL-6. The mechanism behind this activity is believed to involve the modulation of nuclear factor-kappa B (NF-kB) signaling pathways, which play a crucial role in inflammation.

In addition to its anti-inflammatory properties, 1-(3,5-dimethyl-1H-pyrazol-1-yl)methyl-1H-pyrazole-3-carboxylic acid has demonstrated promising anti-cancer effects. Research has indicated that this compound can induce apoptosis in various cancer cell lines by targeting key signaling pathways such as PI3K/Akt and MAPK. These findings suggest that 1-(3,5-dimethyl-1H-pyrazol-1-yl)methyl-1H-pyrazole-3-carboxylic acid may have therapeutic potential in the treatment of inflammatory diseases and cancer.

Potential Applications in Drug Development

The unique chemical structure and biological activities of 1-(3,5-dimethyl-1H-pyrazol-1-yl)methyl-1H-pyrazole-3-carboxylic acid make it an attractive candidate for drug development. In the field of anti-inflammatory drugs, this compound could be developed into novel therapeutics for conditions such as rheumatoid arthritis and inflammatory bowel disease. Its ability to modulate NF-kB signaling pathways provides a strong rationale for its use in these applications.

In cancer research, 1-(3,5-dimethyl-1H-pyrazol-1-yl)methyl-1H-pyrazole-3-carboxylic acid has shown promise as a potential anticancer agent. Preclinical studies have demonstrated its efficacy in inhibiting tumor growth and inducing apoptosis in various cancer models. Further research is needed to optimize its pharmacokinetic properties and evaluate its safety profile in clinical settings.

Clinical Trials and Future Directions

To date, several preclinical studies have been conducted to evaluate the safety and efficacy of 1-(3,5-dimethyl-1H-pyrazol-1-yl)methyl-1H-pyrazole-3-carboxylic acid. These studies have provided valuable insights into its mechanism of action and potential therapeutic applications. However, more extensive clinical trials are necessary to fully assess its safety and efficacy in human subjects.

Ongoing research is focused on optimizing the chemical structure of 1-(3,5-dimethyl-1H-pyrazol-1-y l)meth yl - ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? - - - - - - - - - - - - - - - - - - - - - - - - --m e t h y l--m e t h y l--m e t h y l--m e t h y l--m e t h y l--m e t h y l--m e t h y l--m e t h y l--m e t h y l--m e t h y l--m e t h y l--m e t h y l--m e t h y l--m e t h y l--m e t h y l--m e t h y l--m e t h y l--m e t h y l--m e t h y l--m e t h y l--m e t h yl - m - H - p - y - r - a - z - o - l - e --^{--------------}-carboxylic acid to enhance its pharmacological properties. Strategies such as prodrug design and nanoparticle formulations are being explored to improve its bioavailability and reduce potential side effects.

In conclusion, 1-(3,5-dimethyl-H-pyr az ol-e-y-l)me thyl-H-pr az ol-e-c ar box-yli c ac id (CAS No. 0049286), with its unique chemical structure and promising biological activities, holds significant potential for therapeutic applications in both inflammatory diseases and cancer. Ongoing research efforts are focused on optimizing its properties for clinical use and advancing it through preclinical and clinical trials.

• 5744-59-2(1,5-Dimethyl-1H-pyrazole-3-carboxylic acid)
• 16034-46-1(1-Methyl-1H-pyrazole-5-carboxylic acid)
• 221323-55-3(5-formyl-1-methyl-1H-pyrazole-3-carboxylic acid)
• 221323-58-6(3-formyl-1-methyl-1H-pyrazole-5-carboxylic acid)
• 1006459-10-4(1-{5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-ylmethyl}-1H-pyrazole-3-carboxylic acid)
• 5744-56-9(1,3-Dimethyl-1H-pyrazole-5-carboxylic acid)
• 99012-45-0(null)
• 75092-39-6(1-methyl-1H-pyrazole-3,5-dicarboxylic acid)
• 25016-20-0(1-Methyl-1H-pyrazole-3-carboxylic acid)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)